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Background Hearing loss, which is highly heterogeneous, is the most common 
sensorineural disorder in humans. More than 50% of the causes of deafness are 
attributed to genetic factors. Numerous studies have shown the persistent 
negative impact of deafness on communication and quality of life. Therefore, 
action to optimize performance and maintain or improve hearing ability seems 
necessary. In so doing, interventions are performed after assessing hearing loss. 
The most important intervention is gene therapy; For several genetic diseases, 
gene therapy is a potential treatment that is being investigated. Gene therapy 
will restore the ability to hear by overcoming functional defects caused by 
genetic mutations. Furthermore, gene therapy might potentially be used to 
trigger the regeneration of hair cells by transferring genes required in the cochlea 
for hair cell differentiation. 
Aim: We review recent research about hereditary hearing loss and technologies 
in animal. 
Methods: In this study, we review current reports in clarifying genomics of 
hereditary hearing loss and technologies between 2014 and 2020 in PubMed, 
Scopus, and Google Scholar to create a gene therapy that may soon become a 
treatment choice. We also discuss recent research applied to animal models of 
hearing loss by gene therapy. 
Conclusion: Gene therapy allows for the treatment of sensorineural hearing loss 
by restoring and/or preserving the inner ear cells functioning. Hopeful results 
from recent research have contributed to cochlear gene therapies being created 
for end-use in patients. 
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Loss of hearing is one of the most common 
disorders in humans with a prevalence of 1 in 
1000 births (1). The World Health Organization 
(WHO) reports that over 5% of the world’s 
population suffers from hearing loss, and 34 
million of these are children. It is estimated that 
more than 900 million people will increase by 
2050 (2). Hearing loss implies the inability to 
hear in one or both ears as well as a person with 
normal hearing or a hearing threshold level of 
some more than 25 dB. In addition, hearing loss 
may be categorized as conductive, 
Sensorineural, or combined hearing loss. 
Conductive hearing loss is when there is an 
issue with the propagation of sound waves to 
the cochlea along with the outer ear, the ossicles 
of the middle ear, and the tympanic membrane. 
Sensorineural hearing loss (SNHL) occurs 
when there is an issue in the cochlea converting 
sound stimuli into the electrical signals of 
sensory hair cells (HCs) or when it transmits 
information to the brain about the afferent 
nerves (3). Unfortunately, none of these 
neurosensory cells can regenerate. Therefore, 
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there is no replacement for these cells if are 
damaged due to injury or the normal aging 
process, as a consequence, the loss of these cells 
causes permanent sensory impairment in 
hearing (4-6). Numerous studies have shown 
the persistent negative impact of deafness on 
communication and quality of life. Deafness is 
a risk factor for dementia recently, too. It is also 
related to reduce functional ability and 
increased mortality (7-9). 
Hearing loss is very heterogeneous as a result 
of mutations in several genes, mutations in each 
of these genes are sufficient for the disease to 
occur. It can also be said in the development of 
these disorders, genetic variants play a key role 
(10, 11). In addition, environmental causes such 
as cephalosporin use, noise exposure, middle 
ear infection, and aging should be considered 
(12). The development of new and effective 
methods in the treatment of deafness is 
extremely important. In recent years, gene 
therapy technology has advanced which makes 
it a potential way to treat certain inner ear 
disorders (13). This review article focuses on 
the recent advancement in gene therapy 
development to prevent or restore hearing loss. 
We looked at hearing loss-related genes and 
how genes can be used to retrieve or preserve 




Here, we review current reports in clarifying 
genomics of hereditary hearing loss and 
technologies between 2014 and 2020 in 
PubMed, Scopus, and Google scholar to create 
a gene therapy that may soon become a 
treatment choice. We also discuss recent 
research applied to animal models of hearing 
loss by gene therapy. 
Genetic loss of hearing  
Syndromic versus non-syndromic loss of 
hearing  
Hearing loss can clinically be related to many 
other disorders (syndromic) or be just a sign 
(non-syndromic). Syndromic hearing loss is 
associated with external ear incontinence and 
other organs incontinence. Non-syndromic 
hearing loss does not show any change in the 
visible shape, but if you can have inner or 
middle ear problems. 
Genes of hearing loss 
Between about 50 to 60 percent of children born 
with hearing loss, genes are responsible for 
hearing loss. The total of 121 genes for non-
syndromic hearing loss have been reported to 
date, with 76 autosomal recessive, 49 
autosomal dominant, and 5 X-related genes. 
Currently, an autosomal recessive mutation in 
the STRC is the primary cause of mild to severe 
hearing loss. However, approximately 30% of 
inherited hearing loss is correlated with a 
syndrome. Syndromic hearing silver is 
genetically less heterogeneous than non-
syndromic. There are currently 11 syndromes 
associated with hearing loss with 32 autosomal 
recessive, 16 autosomal dominant, 4 autosomal 
dominant or recessive, and 2 X-linked recessive 
inheritance patterns (14). 
The manifestation of deafness varies in 
autosomal dominant and recessive patterns. 
The onset of deafness is affected in the 
dominant autosome, and this will have trending 
images. While autosomal recessive, deafness 
was more severe than speech. In deafness with 
an autosomal recessive inherited pattern, the 
mutations have a dramatic loss of function, 
resulting in gene products being created or not 
present at all. The goal of gene therapy should 
be to replace the dysfunctional gene with 
functional gene copies. However, in autosomal 
dominant deafness, the type of mutation was 
specifically the functional gain or negative 
mutation, in which there were abnormal 
products or they continued to interfere with 
normal gene products. In such cases, the aim of 
gene therapy should be to eliminate the mutated 
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Gene therapy in the inner ear 
As a model for gene therapy, the inner ear has 
many specific advantages. First, the cochlea is 
well adapted to in vivo gene therapy 
anatomically. Relative cochlear chamber 
isolation reduces the gene's undesirable effects 
on the other structure. The inner ear is filled 
with fluid and allows all functional cells to 
access a transfection reaction. Furthermore, the 
concentration and dosage of complexes injected 
into the cochlea can be achieved easily by 
simply injecting them. Second, numerous 
physiological measurement techniques have 
been developed to evaluate the activity of 
specific cells and to determine the function and 
protection of gene therapy. Third, mutations 
have been reported in this organ in more than 
100 genes that cause deafness, enabling 
structural and physiological study of the effect 
of these genetic mutations on various cells in 
the inner ear (16). Eventually, there are many 
options for treating deafness with gene therapy 
in the cochlea. 
Introduction of vectors for gene therapy in 
cochlea 
The cochlea, surrounded by the bone, is divided 
into three chambers full of fluid called the scala. 
Tympanic scala and vestibular scala have high 
level of sodium and low potassium perilymph. 
At the end of the scalae base is the round 
window. Middle scala comprises low sodium 
and high potassium endolymph. In this 
chamber, there is an organ of Corti. The 
cochlear bone and the round window (RW) are 
two typical access points used for the perfusion 
or injection of vectors into the perilymph. For 
entry to the scala tympani, a cochleostomy may 
be carried out. Both of these techniques have 
been shown to successfully deliver medications 
without hindering the cochlear function of 
rodent. In gene transfer effectiveness, the 
cochleostomy is preferable, whereas the RW is 
less invasive (17). 
Delivery methods in gene therapy 
Non-viral 
Liposomes are the conventional non-viral 
vectors used in inner ear investigation. They are 
simple to produce, can be complicated with any 
size of DNA, and the risk of mutation is very 
low. Evidence has not shown the effects of 
clinically effective transmission. An effective 
vector may result in a broader study of vectors 
and promotors, and the integration of nuclear 
localization sequences and targeting ligands. 
Other techniques, like electroporation (18) and 
the gun gene (19), provided substantial results 
in vitro but were not designed for successful use 
in vivo. 
Adenovirus 
Most research on inner ear gene therapy has 
been done with adenovirus (Ad) vectors that 
can be produced in large concentrations and can 
carry large DNA fragments (8 kb) (20). In vivo 
they are effective in infecting several kinds of 
inner ear cells, including SGCs (21, 22). It is 
essential to know a significant amount of 
variation in specific expression between the 
studies. This difference may be due to changes 
in adenovirus concentrations, vector 
production, and detection of transgenic 
proteins. Ideally, the mechanisms of Ad 
transfection should be identified by studying 
the function of Ad receptors in the inner ear. 
Latest studies have utilized ad vectors in 
animals to avoid deafness. The delivery of Ad-
GDNF protects SGCs from the autogenous 
toxicity of gentamicin (23). The explanation for 
the protective role is unclear, but it can be 
related to the producing proteins. Growth factor 
cytokine (TGF) -B1/GDNF gene therapy 
improves this defense, but which is correlated 
with fibrosis (24). The delivery of Ad-GDNF 
also protects IHCs after severe blood flow 
cessation (25). Antioxidant gene therapy in 
mice has also proved beneficial (26). Models of 
Neurotrophin and antioxidant gene therapy 
promise to cure deafness (17). In several inner 
ear studies, cytotoxicity was found, likely as a 
result of the immune response. Two forms of 
immunosuppressants were initially produced to 
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counter these immune responses: T 
lymphocyte-suppressing inhibitors and anti-
inflammatory steroids. The Ad immune 
response can be inhibited by both types of 
suppressors and development of the second 
transgenic Ad delivery can be allowed (27). 
Adeno-associated virus 
Adeno-associated viral vectors (AAVs) 
generate much lower immune responses than 
Ad vectors. AAV has been shown to mediate up 
to 6 months, at a low level (28). The AAV 
vector can hold 3.5-4.0 kb (kb) DNA (29). 
AAV carriers are less toxic than Ad carriers 
(30), such as Ad vectors, there are differences 
in different profiles. AAV typically infects a 
variety of cochlear tissues, or stria vascularis 
and SGCs (21, 30). In particular reducing the 
immune response makes exploring AAVs more 
appealing. 
Herpes simplex virus 
The virus of herpes simplex is neurotrophic. 
HSV vectors primarily transfect SGC in the 
cochlea (31). NT-3 stimulates neuronal 
survival. One group found that an HSV / NT-3 
vector injected into the vestibular scale could 
boost the survival of SGC 2 days after the 
administration of low-level cisplatin. HSV has 
been shown to reach a dormant process in some 
neuronal cell type, which provides the 
possibility of stable transfection (32). The 
pathogenic nature of the virus and its 
development difficulties are a downside. 
Besides, HSV has affected many people. HSV 
investigation is in the development stage for 
inner ear purposes but has the potential to 
facilitate the survival of neuronal cells. 
Lentivectors 
Lentiviral (LV) vectors can affect non-dividing 
cells, unlike many other retroviral vectors. A 
wide variety of cells, including neural cells, are 
transfected by LVs. Such as AAVs, LVs are a 
relatively low propensity for inflammation. In 
rodent brains, LV-mediated protein expression 
has been seen for up to six months (20). Up to 
14 days of post-injection expression was 
observed in the inner ear, without tissue injury 
(33). After LV/GFP injected into the perilymph, 
the protein was found in cells that were 
available directly by fluids. In vitro transfected 
cells less available such as the spiral ganglia 
and glial cells. According to these early 
findings, the possible applications for this 
vector include the secretion of growth factors 
and antibiotics into the perilymph. Before a 
serious consideration of this vector for 
therapeutic use, the risk of mutagenesis must be 
investigated carefully in the inner ear. 
However, the insertion of genes into the 
chromosome is also helpful in the possible 
treatment for loss of hereditary hearing. For this 
purpose, in treating deafness, LV gene therapy 
holds promise.  
Auditory function control following gene 
therapy 
Gene transfer mechanisms should not be toxic 
and after treatment, cells should be able to 
revert to normal. There are various methods for 
testing the physiology of cochlear. First, 
auditory brainstem response (ABR) to sound 
feedback is used to document activity non-
invasively throughout all areas of the auditory 
pathway, allowing for long-term monitoring. 
The CAP method produces, using an electrode 
mounted on the RW, more response effects than 
the ABR. Numerous otoacoustic emission 
(OAE) tests non-invasively determine the 
cochlear enhancement associated with OHC 
performance. All of these approaches may be 
used to assess the return of auditory function 
following invasive surgery or gene delivery 
(17). 
Discussion 
Although the embryonic stage is a very 
complex period of growth and development; 
however, this stage is the ideal course for 
genetic therapy (34). DNFB gene therapy has 
improved spiral ganglion neurodegeneration 
associated with GJB gene mutations in a mouse 
model. Miwa et al. succeeded in growing the 
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transmute gene into the inner ear of a 
developing mouse fetus, which lacks the 
connexin 30 gene, has persisted since the onset 
of the deaf phenotype (34).  
It should be noted that connexin 30 is one of the 
most important proteins involved in potassium 
ion homeostasis in the cochlea of the inner ear 
and is responsible for creating open 
intercellular relationships that allow it to give 
your small molecules. By electroporation, Miva 
et al. performed the transfer of the Cx 30 gene 
from wild-type mice into the fetal auditory 
vesicles, and induced the expression of a 
strongly critical gene in the developing cochlea; 
as a result, they prevented postpartum deafness 
(35, 36).  
Akil et al. reported the transfer of the VGLUT3 
gene by AAV from wild-type mice to the 
cochlea of mice lacking the gene and observed 
a significant improvement in their auditory 
function (36). It is noteworthy that a deficiency 
in the VGLUT 3 gene causes severe deafness 
due to the loss of glutamate secretion in the 
afferent synapses in the inner hair cells of the 
cochlea (37).  
Recently, according to a Yu et al. report, mice 
that conditionally lacked the GJB 2 gene were 
incurable in the neonatal gene therapy by vector 
gene transfer based on the AAV1 vector. In this 
experiment, the gene transfer time may be 
normal after full expression of the gene but 
before the onset of the deaf phenotype (38).  
In another study, Choi et al. tested the 
SLC26A4 gene, which encodes a membrane-
passing protein called Pendrin, which passes 
through chlorine and iodine and is expressed in 
the inner ear, thyroid, and kidney glands. It is 
noteworthy that mutations in this gene after 
GJB gene significantly contribute to the 
occurrence of non-syndromic deafness with a 
recessive hereditary pattern (39).  
The development of autosomal dominant and 
recessive non-syndromic deafness is also due to 
defects in the TMC1 gene. TMC1 is expressed 
exclusively in the hair cells of the Corti organ 
and 47 mutations in this gene have been 
identified so far, of which only 7 cases have 
been reported in Iranian families (40). Askew et 
al. recently conducted a study on TMC gene 
therapy. They inserted the gene into the ear hair 
cells in mice with mutations in the gene using 
the AVV vector and eventually observed the 
return of sensory transmissions, auditory 
brainstem responses, and rapid sound responses 
in deaf mice. This study demonstrates the gene 
therapy of TMC gene as a suitable strategy for 
hearing restoration in deaf patients caused by 
mutations in this gene (41). 
 
Conclusion 
In general, there are various and useful methods 
in the treatment of hearing loss, however, for 
better efficiency of treatment methods and more 
effective improvement of this type of disorders, 
access to new and targeted technologies of 
molecular therapies have evolved and more 
hope than prompted the recovery of this type of 
genetic disorder. Gene therapy allows for the 
treatment of sensorineural hearing loss by 
restoring and/or preserving the inner ear cells 
functioning. Hopeful results from recent 
research have contributed to cochlear gene 
therapies being created for end-use in patients. 
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